MA39032B2 - Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë - Google Patents

Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë

Info

Publication number
MA39032B2
MA39032B2 MA39032A MA39032A MA39032B2 MA 39032 B2 MA39032 B2 MA 39032B2 MA 39032 A MA39032 A MA 39032A MA 39032 A MA39032 A MA 39032A MA 39032 B2 MA39032 B2 MA 39032B2
Authority
MA
Morocco
Prior art keywords
phenoxy
oxazolo
pyrimidin
chloro
dimethyl
Prior art date
Application number
MA39032A
Other languages
English (en)
Other versions
MA39032A1 (fr
Inventor
Philip Janiak
Bruno Poirier
Dieter Kadereit
Véronique Briand
Sabine Gratzer
Thomas Huebschle
Ashfaq Parkar
Matthias Schaefer
Paulus Wohlfart
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49488539&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39032(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA39032A1 publication Critical patent/MA39032A1/fr
Publication of MA39032B2 publication Critical patent/MA39032B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne de l'acide {4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique ou un sel pharmaceutiquement acceptable de celui-ci destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë) (ira). L'invention porte également sur un médicament et une composition pharmaceutique de celui-ci.
MA39032A 2013-10-15 2014-10-15 Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë MA39032B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20130306417 EP2862574A1 (fr) 2013-10-15 2013-10-15 Acide {4-[5-(3-chloro-phénoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-diméthyl-phénoxy}-acétique pour son utilisation dans la prévention ou le traitement de l'insuffisance rénale aiguë
PCT/EP2014/072078 WO2015055694A1 (fr) 2013-10-15 2014-10-15 Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë

Publications (2)

Publication Number Publication Date
MA39032A1 MA39032A1 (fr) 2017-04-28
MA39032B2 true MA39032B2 (fr) 2020-10-28

Family

ID=49488539

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39032A MA39032B2 (fr) 2013-10-15 2014-10-15 Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë

Country Status (25)

Country Link
US (1) US9782411B2 (fr)
EP (2) EP2862574A1 (fr)
JP (1) JP6458016B2 (fr)
KR (1) KR102348608B1 (fr)
CN (1) CN105658220B (fr)
AR (1) AR098028A1 (fr)
AU (1) AU2014336254B9 (fr)
BR (1) BR112016007669B1 (fr)
CA (1) CA2926211C (fr)
CL (1) CL2016000724A1 (fr)
CR (1) CR20160172A (fr)
DK (1) DK3057591T3 (fr)
EA (1) EA032012B1 (fr)
ES (1) ES2898403T3 (fr)
FI (1) FI3057591T3 (fr)
HK (1) HK1225611A1 (fr)
IL (2) IL244686B (fr)
MA (1) MA39032B2 (fr)
MX (1) MX2016004778A (fr)
PH (1) PH12016500563A1 (fr)
PT (1) PT3057591T (fr)
SG (1) SG11201602263TA (fr)
TN (1) TN2016000110A1 (fr)
TW (1) TWI685340B (fr)
WO (1) WO2015055694A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190062502A (ko) * 2016-10-05 2019-06-05 미토브리지, 인크. 급성 신장 손상을 치료하는 방법
CN106905348B (zh) * 2017-02-13 2018-12-04 牡丹江医学院 一种预防和治疗急性肾损伤的药物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10033353A1 (de) 2000-07-08 2002-01-24 Aventis Pharma Gmbh Breit einsetzbares Verfahren zur Identifizierung von Modulatoren von G-Protein gekoppelten Rezeptoren
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CN100567275C (zh) 2003-11-21 2009-12-09 埃科特莱茵药品有限公司 作为免疫抑制剂的5-(苯基-(z)-亚基)-噻唑烷-4-酮衍生物
RS53254B (en) 2010-01-14 2014-08-29 Sanofi CARBOXYLIC ACID DERIVATIVES WITH 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING

Also Published As

Publication number Publication date
AU2014336254B2 (en) 2020-02-06
ES2898403T3 (es) 2022-03-07
EA032012B1 (ru) 2019-03-29
AU2014336254B9 (en) 2020-02-20
KR20160060759A (ko) 2016-05-30
AR098028A1 (es) 2016-04-27
IL282097A (en) 2021-05-31
PT3057591T (pt) 2021-12-09
MA39032A1 (fr) 2017-04-28
FI3057591T3 (fi) 2024-10-08
JP6458016B2 (ja) 2019-01-23
PH12016500563A1 (en) 2016-05-23
TW201605453A (zh) 2016-02-16
NZ719089A (en) 2020-09-25
WO2015055694A1 (fr) 2015-04-23
BR112016007669B1 (pt) 2023-01-10
TN2016000110A1 (en) 2017-07-05
EP3057591A1 (fr) 2016-08-24
MX2016004778A (es) 2017-01-11
JP2016534986A (ja) 2016-11-10
DK3057591T3 (da) 2021-12-13
CN105658220A (zh) 2016-06-08
TWI685340B (zh) 2020-02-21
SG11201602263TA (en) 2016-04-28
CA2926211C (fr) 2022-03-29
US9782411B2 (en) 2017-10-10
IL244686A0 (en) 2016-04-21
EP3057591B1 (fr) 2021-09-08
KR102348608B1 (ko) 2022-01-06
IL244686B (en) 2021-04-29
CR20160172A (es) 2016-06-08
BR112016007669A2 (pt) 2017-08-01
EP2862574A1 (fr) 2015-04-22
HK1225611A1 (zh) 2017-09-15
CL2016000724A1 (es) 2016-09-23
EA201690762A1 (ru) 2016-07-29
CN105658220B (zh) 2019-04-19
CA2926211A1 (fr) 2015-04-23
US20160235756A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
BR112015029455A2 (pt) compostos químicos
BR112013031098A2 (pt) halogeno-alquil-1,3 oxazinas como inibidores de bace1 e/ou bace2
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
SI2582683T1 (en) Treatment of gout and hyperuricaemia
BR112014015630A2 (pt) fluorometil-5,6-di-hidro-4h-[1,3]oxazinas
MA44948A1 (fr) Inhibiteurs de bace 1
MA43828B1 (fr) Agents thérapeutiques pour maladies neurodégénératives
MA39146A1 (fr) Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39032A1 (fr) Acide 4- [5- (3-chloro-phénoxy) -oxazolo [5,4-d] pyrimidin -2-yl] -2,6-diméthyl-phénoxy}-acétique destiné à être utilisé dans la prévention ou le traitement d'une insuffisance rénale aiguë
EA201591435A1 (ru) Новая композиция соединения ацетаминофена без побочного эффекта на печень
MA45639B1 (fr) Combinaison d'antagonistes purs du récepteur 5-ht6 avec des inhibiteurs d'acétylcholinestérase
MA32299B1 (fr) Utilisation de la dronedarone pour preparer un medicament pour le traitement de patients ayant une arythmie et ayant une augmentation du taux de creatinine due a l'administration de dronedarone
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA35636B1 (fr) Formulation à libération immédiate de 4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-méthyl- 1h-imidazol-1-yl)-3-(trifluorométhyl)phényl]benzamide
FI3302451T3 (fi) Palmitoyylietanoliamidia (pea) ja lykopeenia sisältävä yhdistelmä käytettäväksi inflammatoristen sairauksien hoidossa
MA33455B1 (fr) Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux
MA46778B1 (fr) Composition intranasale comprenant de la bétahistine
MA35850B1 (fr) Nouvelle utilisation thérapeutique d'antagonistes du récepteur p75
MA39833B1 (fr) Nouvelle utilisation du n,n-bis-2-mercaptoéthyl isophtalamide
EA201391827A1 (ru) Соединения [1,2,4]тиадиазин 1,1-диоксида для снижения мочевой кислоты в сыворотке
FR2992863A1 (fr) Composition pharmaceutique pour le traitement du cancer
MA45615B1 (fr) Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale